What is the recommended treatment regimen for sarcoidosis?

Treatment of Sarcoidosis

For patients with symptomatic or organ-threatening sarcoidosis, initiate glucocorticoids (prednisone 20-40 mg daily) as first-line therapy, add methotrexate early as a steroid-sparing agent within 3-6 months, and escalate to infliximab for refractory disease. 1

When to Treat vs. Observe

Not all patients require treatment—nearly half of sarcoidosis patients never need systemic therapy. 1

Initiate treatment for:

• Symptomatic disease causing impaired quality of life 1
• Organ-threatening manifestations with risk of permanent disability or mortality 1
• Progressive pulmonary disease with declining FVC 1
• Cardiac involvement with heart block, dysrhythmias, or cardiomyopathy 1
• Clinically significant neurosarcoidosis 1
• Cosmetically important cutaneous lesions uncontrolled by topical therapy 1

Do not treat asymptomatic pulmonary sarcoidosis—corticosteroids do not alter the natural course in these patients. 1

First-Line Therapy: Glucocorticoids

Start prednisone 20-40 mg daily for acute or chronic phenotypes anticipated to progress. 1

• Allow 3-6 months to assess therapeutic response before escalating 1
• Taper to ≤10 mg daily as soon as disease control is achieved 1
• Consider hydroxychloroquine specifically for hypercalcemia or skin disease 1

Recent evidence challenges prednisone primacy: A 2025 randomized trial demonstrated methotrexate was noninferior to prednisone for first-line treatment of pulmonary sarcoidosis, with methotrexate showing a different side-effect profile (nausea, fatigue, liver function abnormalities) compared to prednisone (weight gain, insomnia, increased appetite). 2 This suggests methotrexate may be considered as initial therapy in selected patients, though guidelines have not yet incorporated this finding.

Second-Line Therapy: Methotrexate

Add methotrexate when:

• Disease progression occurs despite 3-6 months of glucocorticoids 1
• Unacceptable glucocorticoid side effects develop 1
• Inability to taper prednisone below 10 mg daily 1

Dosing and administration:

• Start at low doses and titrate as needed 1
• Consider 15-25 mg weekly, with subcutaneous administration improving bioavailability over oral 3
• Add folic acid supplementation to reduce side effects 3, 4
• Allow 3-6 months to assess response before further escalation 1, 3

Alternative second-line agents (if methotrexate fails or causes toxicity): azathioprine, mycophenolate mofetil, or leflunomide, though these did not reach consensus in guidelines. 1

Third-Line Therapy: Anti-TNF Biologics

Escalate to infliximab when:

• Continued disease despite glucocorticoids plus methotrexate 1
• Advanced disease phenotype with significant organ involvement 1

Infliximab is the preferred biologic with the strongest evidence base over adalimumab or rituximab. 3

Dosing:

• Loading: 5 mg/kg at weeks 0,2, and 6 3
• Maintenance: Continue every 4-8 weeks 3
• Combine with low-dose methotrexate to reduce autoantibody formation 1, 3
• Continue for 2-3 years in responders before considering discontinuation 1

Before initiating anti-TNF therapy:

• Screen for tuberculosis (interferon-γ test, history of TB/latent TB) 1
• Administer pneumococcal and influenza vaccines 1

Avoid etanercept—it is ineffective for sarcoidosis. 3

Organ-Specific Treatment Algorithms

Pulmonary Sarcoidosis

• Major involvement with high mortality/disability risk: Glucocorticoids strongly recommended 1
• Continued disease on steroids: Add methotrexate 1
• Refractory to steroids + methotrexate: Add infliximab 1
• Inhaled corticosteroids may provide symptomatic relief for cough/asthma-like symptoms but discontinue if ineffective 3

Cardiac Sarcoidosis

• Any functional cardiac abnormality (heart block, dysrhythmias, cardiomyopathy): Strongly recommend glucocorticoids with or without other immunosuppressives 1
• This is a strong recommendation despite very low quality evidence due to high mortality risk 1

Neurosarcoidosis

• First-line: Glucocorticoids (strong recommendation) 1
• Second-line: Add methotrexate for continued disease 1
• Third-line: Add infliximab after failure of glucocorticoids plus methotrexate (or azathioprine/mycophenolate) 1
• More aggressive treatment approach warranted due to high morbidity 3

Cutaneous Sarcoidosis

• Cosmetically important lesions uncontrolled by topical therapy: Consider oral glucocorticoids 1
• Hydroxychloroquine particularly effective for skin manifestations 3
• Refractory to glucocorticoids: Add infliximab 1, 3
• Topical tacrolimus 0.1% may alleviate localized erythema and itching 3

Treatment Duration and Tapering

Glucocorticoid tapering:

• Taper to ≤10 mg daily as soon as disease stabilizes 1
• Discontinue if possible once biologics achieve control 1

Biologic discontinuation:

• Consider after 2-3 years of disease stability 1
• Discontinue for treatment toxicity or failure to achieve stabilization 1

Relapse risk: 20-80% of patients relapse when glucocorticoids are stopped after 1-2 years. 4

Infection Prophylaxis

Pneumocystis pneumonia prophylaxis (trimethoprim-sulfamethoxazole):

• Patients on ≥20 mg prednisone-equivalent daily plus methotrexate for >6 months 3
• Multiple immunosuppressive agents 1
• Patients at high risk for infection 1

Tuberculosis prophylaxis:

• Positive interferon-γ test 1
• History of TB or latent TB 1

Sarcoidosis-Associated Fatigue

Pulmonary rehabilitation and/or inspiratory muscle strength training for 6-12 weeks is suggested over immunosuppressants for troublesome fatigue. 1

Advanced/Refractory Disease

Consider lung transplantation for:

• Severe disease unresponsive to therapy 1
• Low and worsening pulmonary function tests 1
• Pulmonary hypertension 1

Repository corticotrophin injection or CLEAR therapy (concomitant levofloxacin, ethambutol, azithromycin, rifampin) may be considered for advanced phenotypes, though no consensus was reached. 1

Critical Pitfalls to Avoid

Avoid prolonged corticosteroid monotherapy—this fails to address disease progression and causes significant toxicity. 1, 3, 4

Allow sufficient time (3-6 months) to assess response to each therapy before escalating—premature escalation wastes therapeutic opportunities. 1, 3

Do not treat asymptomatic disease—treatment does not alter natural history and exposes patients to unnecessary toxicity. 1

Screen for TB before anti-TNF therapy—failure to do so risks reactivation. 1, 3

Recognize that obesity and smoking are independent predictors of recurrence (OR 1.9 and 2.3, respectively)—counsel patients on weight management and smoking cessation. 5